protection programs. Thus, unlike other organizations, AFDO has a unique perspective on the infrastructure, capacity, strengths, and needs of State and local food protection programs.

• AFDO has successful experience in carrying out national efforts that focus on the needs of State and local regulatory agencies. FDA has used the data from the initial AFDO State Food Safety Resource Survey, AFDO model codes, and training programs such as the Seafood HACCP training program certified through AFDO. AFDO has also developed the AFDO Recall Manual and many other training programs and initiatives with the Centers for Disease Control, the U.S. Department of Agriculture, and others in meat and poultry processing at retail. AFDO also has industry associate members.

C. Award Amount

The total amount of funding available for fiscal years 2008 through 2010 is $250,000. This cooperative agreement will award up to $250,000 in total (direct plus indirect) costs for a 3-year cooperative agreement.

D. Length of Support

The length of support for this project will be 3 years.

E. Cost Sharing or Matching

Cost sharing is not required.

IV. Application and Submission

A. Application Information

Applications must be prepared using the most current SF424 (Research and Related) (also referred to as the ''SF424 (R&R)'', which is part of the Public Health Service, PHS 5161–1 form. Applications must have a Dun and Bradstreet Data Universal Numbering System (DUNS) number as the universal identifier when applying for Federal grants or cooperative agreements. The DUNS number can be obtained by calling 866–705–5711 or through the Web site at *http://www.dnb.com/us/*. (FDA has verified the Web site addresses throughout this document, but we are not responsible for any subsequent changes to the Web sites after this document publishes in the **Federal Register**.)

Applications must be prepared using the forms found in the SF424 R&R instructions for preparing a nonmodular research grant application. Submit a signed, typewritten original of the paper application, including the checklist, three signed photocopies, and appendix material in one package to: Marc Pitts (see **FOR FURTHER INFORMATION CONTACT**).

If you experience technical difficulties with your online submission, you should contact either Marc Pitts (see **FOR FURTHER INFORMATION CONTACT**), or the Grants.gov Customer Support Center by e-mail at *support@grants.gov* or by phone at 1–800–518–4726.

Information collection requirements requested on Form (SF–424) PHS 5161–1, expiration date of January 31, 2009, have been sent by the PHS to the Office of Management and Budget (OMB) and have been approved and assigned OMB control number OS–4040–0004.

B. Submission Dates and Times

The application receipt date is 30 days after the publication of the funding opportunity in the **Federal Register**. Applications will be accepted from 8 a.m. to 4:30 p.m. e.s.t., Monday through Friday, until the established receipt date. Applications submitted electronically must be received by the close of business on the established receipt date. No addendum material will be accepted after the established receipt date.

C. Intergovernmental Review

The regulations issued under Executive Order 12372, Intergovernmental Review of Federal Programs (45 CFR part 100) apply. Applicants (other than federally recognized tribal governments) should contact the State's Single Point of Contact (SPOC) as early as possible to alert the SPOC to the prospective application(s) and to receive any necessary instructions on the State's review process. A current listing of SPOCs is located at *http//www.whitehouse.gov/omb/grants/spoc.html*. The SPOC should send any State review process recommendations to the FDA administrative contact (see **FOR FURTHER INFORMATION CONTACT**). The due date for the State process recommendations is no later than 60 days after the application receipt date. FDA does not guarantee accommodation or explanation of SPOC comments that are received after the 60-day cutoff.

D. Funding Restrictions

This cooperative agreement is not to fund annual, regional, or State meetings of AFDO, travel for other than project employees, equipment other than consumables or as outlined in the application, or any remodeling or capital improvement to office location or space.

E. Central Contractor Registration

Applicants must register with the Central Contractor Registration (CCR) database. This database is a government-wide warehouse of commercial and financial information for all organizations conducting business with the Federal Government. Registration with CCR is a mandatory requirement and is consistent with the government-wide management reform to create a citizen-centered Web presence and to build e-gov infrastructures in and across agencies to establish a ''single face to industry.'' The preferred method for completing a registration is through the World Wide Web at *http://www.ccr.gov*. This Web site provides a CCR handbook with detailed information on data you will need prior to beginning the online preregistration, as well as steps to walk you through the registration process. You must have a DUNS number to begin your registration. The CCR registration process can also be found under the ''Organization Registration'' page of Grants.gov at *http://www.grants.gov/applicants/organization_registration.jsp*.

F. Copyright Material

Applicant and applicants' subgrantees and subcontractors must ensure that any projects developed in whole or in part with Federal funds may be made available to other State, territorial, local, and tribal regulatory agencies by FDA or its agents. Any copyrighted or copyrightable works shall be subject to a royalty-free, nonexclusive, and irrevocable license to the Federal Government to reproduce, publish, or otherwise use them, and to authorize others to do so for Federal Government purposes.

Dated: July 15, 2008.

Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E8–16818 Filed 7–22–08; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2008–N–0359]

Food Safety and Security Monitoring Project

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA), Office of Regulatory Affairs (ORA), Division of Federal-State Relations (DFSR), is announcing the availability of cooperative agreements for equipment, supplies, personnel, training, and facility upgrades to Food Emergency

Response Laboratory Network (FERN) chemistry laboratories of State, local, and tribal governments. The cooperative agreements are to enable the analyses of foods and food products in the event that redundancy and/or additional laboratory surge capacity is needed by FERN for analyses related to chemical terrorism. These grants are also intended to expand participation in networks to enhance Federal, State, local, and tribal food safety and security efforts.

DATES: Receipt Date: Applications are due within 30 days after the publication of the funding opportunity in the **Federal Register**.

FOR FURTHER INFORMATION CONTACT:

For issues regarding the administrative and financial management aspects of this notice: Marc Pitts, Division of Acquisition Support and Grants, Food and Drug Administration, 5630 Fishers Lane, Rockville, MD 20857, 301–827–7162, e-mail: *Marc.Pitts@fda.hhs.gov;*

Regarding the programmatic aspects of this notice: Jennifer Gabb, Division of Federal-State Relations, Food and Drug Administration (HFC–150), 5600 Fishers Lane, rm. 12–07, Rockville, MD 20857, 301–827–2899, e-mail: *jennifer.gabb@fda.hhs.gov*; and

For technical aspects of this notice: Dean Turco, Division of Field Science, Food and Drug Administration (HFC–140), 5600 Fishers Lane, rm. 12–41, Rockville, MD 20857, 301–827–4097, e-mail: *dean.turco@fda.gov*.

SUPPLEMENTARY INFORMATION:

I. Funding Opportunity Description

Announcement Type: New Competing Cooperative Agreement (U18) under a Limited Competition

Request for Applications (RFA) Number: RFA-FD–08–009

Catalog of Federal Catalog of Federal Domestic Assistance Number: 93.448

ORA is the primary inspection and analysis component of FDA and has approximately 1,600 investigators, inspectors, and analysts who cover the country's approximately 95,000 FDA-regulated businesses. These investigators inspect more that 15,000 facilities per year and ORA laboratories analyze several thousand samples per year. ORA conducts special investigations, conducts food inspection recall audits, performs consumer complaint inspections, and collects samples of regulated products. Increasingly, ORA has been called upon to expand the testing program addressing the increasing threat to food safety and security through intentional chemical terrorism events. Toward these ends, ORA has developed a suite of chemical screening and analysis methodologies that are used to evaluate foods and food products in such situations. However, in the event of a large-scale emergent incident, analytical sample capacity in ORA field laboratories has a finite limit. Information from ongoing relationships with State partners indicates limited redundancy in State food testing laboratories, both in terms of analytical capabilities and analytical sample capacity. Several State food testing laboratories lack the specialized equipment to perform the analyses and/or the specific methodological expertise in the types of analyses performed for screening foods and food products involving chemical terrorism events.

The events of September 11, 2001, reinforced the need to enhance the security of the U.S. food supply. Congress responded by passing the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (the Bioterrorism Act) (Public Law 107–188), which President George W. Bush signed into law on June 12, 2002. The Bioterrorism Act is divided into the following five titles:

Title I—National Preparedness for Bioterrorism and Other Public Health Emergencies,

Title II—Enhancing Controls on Dangerous Biological Agents and Toxins,

Title III—Protecting Safety and Security of Food and Drug Supply,

Title IV—Drinking Water Security and Safety, and

Title V—Additional Provisions.

Subtitle A of the Bioterrorism Act, Protection of Food Supply, section 312—Surveillance and Information Grants and Authorities, amends part B of Title III of the Public Health Service Act to authorize the Secretary of Health and Human Services (the Secretary) to award grants to States and tribes to expand participation in networks to enhance Federal, State, and local food safety efforts. This may include meeting the costs of establishing and maintaining the food safety surveillance, technical, and laboratory capacity needed for such participation.

Project Emphasis

The goal of ORA's cooperative agreement program is to complement, develop, and improve State, local, and tribal food safety and security testing programs. This will be accomplished through the provision of equipment, supplies, personnel, facility upgrades, training in current food testing methodologies, participation in proficiency testing to establish additional reliable laboratory sample analysis capacity, analysis of surveillance samples, and in cooperation with FDA, participation in method enhancement activities designed to extend analytical capabilities. In the event of a large-scale chemical terrorism event affecting foods or food products, the recipient may be required to perform selected chemical analyses of domestic and imported food samples collected and supplied to the laboratory by FDA or other government agencies through FDA. These samples may consist of, but are not limited to, the following: Vegetables and fruits (fresh and packaged), juices (concentrate and diluted), grains and grain products, seafood and other fish products, milk and other dairy products, infant formula, baby foods, bottled water, condiments, and alcoholic products (beer, wine, scotch).

II. Award Information

Mechanism of Support

All grant application projects that are developed at State, local, and tribal levels must have national implication or application that can enhance Federal food safety and security programs. At the discretion of FDA, successful project formats will be made available to interested Federal, State, local, and tribal government FERN laboratories.

There are four key project areas identified for this effort that must be addressed:

1. The use of gas chromatography/mass spectrometry analysis for the screening and identification of poisons, toxic substances, and unknown compounds in foods;

2. The use of liquid chromatography/mass spectrometry analysis for the screening and identification of poisons, toxic substances, and unknown compounds in foods;

3. The use of inductively coupled plasma/mass spectrometry analysis for the screening and identification of heavy metals and toxic elements in foods; and

4. The use of enzyme-linked immunosorbent assay and other antibody-based analyses for the screening and identification of unknown toxins in foods.

FDA will support the projects covered by this document under the authority of section 312 of the Bioterrorism Act. This program is described in the Catalog of Federal Domestic Assistance under number 93.448.

Support will be in the form of a cooperative agreement. Substantive

involvement by the awarding agency is inherent in the cooperative agreement award. Accordingly, FDA will have substantial involvement in the program activities of the project funded by the cooperative agreement. Substantive involvement includes, but is not limited to, the following: (1) How often samples will be sent, (2) directions on how tests should be executed, (3) onsite monitoring, (4) supply of equipment, (5) FDA training on processes, and (6) enhancement and extension of analytical methodology.

FDA will provide specific procedures and protocols for the four project areas to be used for the analysis of toxic chemicals and toxins in food.

FDA will provide guidance on the specific foods to be collected for analysis by the successful applicant. FDA will purchase and have all needed major equipment for the four project areas delivered to the awardee's laboratory. The equipment purchased will remain the property of FDA until such time as it is released as surplus property.

Only proposed projects designed to address all four project areas will be considered for funding. Applicants may also apply for only facility upgrades, personnel, training, method extension, and surveillance sample analysis if they have the necessary equipment and it will be available for these projects. These grants are not to fund or conduct food inspections for food safety regulatory agencies.

It should be emphasized that in all of the projects, there is a particular desire to promote a continuing, reliable capability and capacity for laboratory sample analyses of foods and food products for the rapid detection and identification of toxic chemicals or toxins. With this in mind, it is desirable that sample analyses will be completed no later than 2 weeks after receipt, and the results will be reported to FERN. The format and reporting media will be established by FERN. Shorter timeframes may be sought for special testing such as proficiency tests or special assignments.

III. Eligibility Information

A. Eligible Applicants

This cooperative agreement program is only available to State, local, and tribal government FERN laboratories that currently are not funded under this cooperative agreement and is authorized by section 312 of the Bioterrorism Act. All grant application projects that are developed at State, local, and tribal levels must have national implication or application that can enhance Federal food safety and security programs. At the discretion of FDA, successful project formats will be made available to interested Federal, State, local, and tribal government FERN laboratories.

B. Cost Sharing or Matching

Cost sharing is not required.

IV. Application and Submission

A. Application Information

In order to apply electronically, the applicant must complete the following steps:

Step 1: Obtain a Dun & Bradstreet Number (DUNS Number)

Same day. Your organization will need to obtain a DUNS Number. If your organization doesn't already have one, go to the Dun & Bradstreet Web site at *http://fedgov.dnb.com/webform*.

Step 2: Register with the Central Contractor Registry (CCR)

Two days or up to 1 to 2 weeks. Ensure that your organization is registered with the CCR at *http://www.ccr.gov*. If your organization is not already registered, an authorizing official of your organization must register. You will not be able to move on to Step 3 until this step is completed.

Step 3: Obtain Username and Password

Same day. Create a username and password with Operational Research Consultants (ORC), the Grants.gov credential service provider. Use your organization's DUNS Number to access the ORC Website at *http://apply07.grants.gov/apply/OrcRegister*.

Step 4: Grants.gov Registration

Same day. Register with Grants.gov at *https://apply07.grants.gov/apply/GrantsgovRegister* to open an account using the username and password you received from ORC.

Step 5: Authorized Organization Representative (AOR) Authorization

Time depends on responsiveness of your E-Business Point of Contact (E-Biz POC). The E-Biz POC at your organization must respond to the registration e-mail from Grants.gov and login at Grants.gov to authorize you as an AOR. Please note that there can be more than one AOR for your organization. In some cases the E-Biz POC is also the AOR for an organization.

Step 6: Track AOR Status

At any time, you can track your AOR status at the Applicant home page of Grants.gov in ''Quick Links'' by logging in with your username and password (*https://apply07.grants.gov/apply/ApplicantLoginGetID*).

FDA is accepting new applications for this program electronically via Grants.gov. Applicants must apply electronically by visiting the Web site *http://www.grants.gov* and following instructions under ''APPLY FOR GRANTS.'' The required application SF424, which is part of the PHS 5161–1 form, can be completed and submitted online by selecting Step 1: ''Download a Grant Application Package,'' then by entering the funding opportunity number ''RFA–FD–08–009.'' The ''Selected Grant Applications For Download'' page will provide you with the Additional Resources downloads for Adobe Reader and PureEdge Viewer as well as the download to the ''Instructions & Application'' hyperlink.

B. Content and Form of Application

1. Content of Application

The SF424 PHS–5161 has several components. Some components are required, others are optional. The forms package associated with this request for application (*http://www.Grants.gov/Apply*) includes all applicable components. If you experience technical difficulties with your online submission you should contact either Marc Pitts (see **FOR FURTHER INFORMATION CONTACT**) or the Grants.gov Customer Support Center by e-mail at *support@grants.gov* or by phone at 1–800–518–4726.

2. Format for Application

All applications must be submitted electronically through Grants.gov. Paper applications will not be accepted. The application must be an SF424–PHS–5161. The narrative portion, excluding appendices, of the application may not exceed 100 pages in length and must be single-spaced in 12-point font. The appendices should also not exceed 100 pages in length (separate from the narrative portion of the application).

Information collection requirements requested on Form (SF–424) PHS 5161–1, expiration date of January 31, 2009, have been sent by the Public Health Service (PHS) to the Office of Management and Budget (OMB) and have been approved and assigned OMB control number OS–4040–0004.

C. Submission Dates and Times

The application receipt date is 30 days after the publication of the funding opportunity in the **Federal Register**. Applications will be accepted from 8 a.m. to 4:30 p.m., Monday through Friday, until the receipt date. Applications submitted electronically must be received by close of business on

the receipt date. No addendum material will be accepted after the receipt date.

D. Intergovernmental Review

The regulations issued under Executive Order 12372, Intergovernmental Review of Department of Health and Human Services Programs and Activities (45 CFR part 100), apply to the Food Safety and Security Monitoring Project. Applicants (other than federally recognized Indian tribal governments) should contact the State's Single Point of Contact (SPOC) as early as possible to alert the SPOC to the prospective application(s) and to receive any necessary instructions on the State's review process. A current listing of SPOCs is included in the application kit or at *http://www.whitehouse.gov/omb/grants/spoc.html*. (FDA has verified the Web site address, but FDA is not responsible for subsequent changes to the Web site after this document publishes in the **Federal Register**.) The SPOC should send any State review process recommendations to the FDA administrative contact (see **FOR FURTHER INFORMATION CONTACT**). The due date for the State process recommendations is no later than 60 days after the application receipt date. FDA does not guarantee accommodation or explaination of SPOC comments that are received after the 60-day cutoff.

E. Funding Restrictions

These grants are not to fund or conduct food inspections for food safety regulatory agencies. They may not be utilized for new building construction, however, remodeling of existing facilities is allowed, provided that remodeling costs do not exceed 25 percent of the grant award amount.

Dated: July 7, 2008.

Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E8–16820 Filed 7–22–08; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2008–N–0038]

Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Postponement of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is postponing the meeting of the Peripheral and Central Nervous Drugs Advisory Committee scheduled for August 6 and 7, 2008. This meeting was announced in the **Federal Register** of July 8, 2008 (73 FR 39017). The postponement is due to difficulties in empanelling the necessary experts due to both scheduling conflicts and conflict-of-interest issues.

FOR FURTHER INFORMATION CONTACT: Diem-Kieu Ngo, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, FAX: 301–827–6776, e-mail: *diem.ngo@fda.hhs.gov*, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512543. Please call the Information Line for up-to-date information on this meeting.

Dated: July 17, 2008.

Randall W. Lutter,

Deputy Commissioner for Policy.

[FR Doc. E8–16814 Filed 7–22–08; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences, Special Emphasis Panel, Drug Docking and Screening Resource.

Date: August 11, 2008.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications

Place: National Institutes of Health, Natcher Building, 45 Center Drive 3AN12A, Bethesda, MD 20892. (Telephone Conference Call)

Contact Person: Mona R. Trempe, PhD., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3AN12, Bethesda, MD 20892, 301-594-3998, *trempemo@mail.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: July 14, 2008.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E8–16512 Filed 7–22–08; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse, Special Emphasis Panel, Mechanism for Time-Sensitive Research Opportunities.

Date: August 5, 2008.

Time: 1 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6101 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call)

Contact Person: Gerald L. McLaughlin, PhD, Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Blvd., Bethesda, MD 20892–8401, 301–402–6626, *gm145a@nih.gov*.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.